According to a recent LinkedIn post from Ro, the company is now offering Foundayo, Eli Lilly and Company’s latest GLP-1 pill, through its platform. The post notes that Foundayo can be taken at any time of day with or without food, and can be delivered directly to consumers’ homes, with Ro indicating it aims to provide what it describes as competitive cash pricing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights the continued build-out of Ro’s GLP-1 formulary, positioning its platform as a distribution and access channel for newer obesity and metabolic treatments. For investors, this move suggests Ro is seeking to deepen its role in the fast-growing GLP-1 market, which could support revenue growth and patient acquisition if consumer demand and supply from branded manufacturers remain strong.
The post also implies that Ro is targeting both new patients and those maintaining weight-loss results, which may help improve customer lifetime value and recurring revenue potential. By aligning with a major pharmaceutical player’s innovation pipeline, Ro may enhance its competitive standing among digital health and telehealth peers that are also racing to offer GLP-1 therapies, though profitability will depend on unit economics, pricing power, and adherence rates.